Skip to content

Reported November 13, 2025 · Before market open

EPS-$0.33Beat by $0.08
EPS estimate-$0.41

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.36

Financials

Q3 2025

Income statement

See full
Operating income-$36.7M+4.3%
Net income-$32.6M+5.7%
EPS (diluted)-$0.33+32.7%

Balance sheet

See full
Cash & equivalents$49.7M+12.3%
Total debt$3.3M+5.8%
Total equity$406.9M+48.5%
Total assets$431.2M+42.7%

Cash flow

See full
Operating cash flow-$25.1M+12.8%
CapEx$35.0K-91.6%
Free cash flow-$25.1M+13.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.17B+61.6%
Enterprise value$1.12B+64.6%

Returns & leverage

See full
Return on equity-39.7%-4.8pp
Debt / equity0.0×
Current ratio14.6×+1.5×

Versus estimates

Ask the moment Oric Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Oric Pharmaceuticals, Inc. report Q3 2025 earnings?
Oric Pharmaceuticals, Inc. (ORIC) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Oric Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Oric Pharmaceuticals, Inc. reported eps of $-0.33 for Q3 2025.
Did Oric Pharmaceuticals, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.41 by $0.08.
How did Oric Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 32.7% from $-0.49.
Where can I find Oric Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-280247) and the 10-Q periodic report (0001193125-25-280234) directly on SEC EDGAR. The filing index links above go to sec.gov.